Literature DB >> 10723138

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.

F Dion1, A M Mes-Masson, R J Seymour, D Provencher, P N Tonin.   

Abstract

Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723138     DOI: 10.1038/sj.onc.1203463

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

2.  Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.

Authors:  I Brozek; K Ochman; J Debniak; L Morzuch; M Ratajska; M Stepnowska; M Stukan; J Emerich; J Limon
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

3.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

4.  Down-regulation in multiple human cancers of a novel gene, DMHC, from 17q25.1 that encodes an integral membrane protein.

Authors:  I Mikami; H Harada; H Nagai; M Tsuneizumi; Y Nobe; K Koizumi; S Sugano; S Tanaka; M Emi
Journal:  Jpn J Cancer Res       Date:  2001-04

5.  Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Authors:  P Wojnarowicz; K Gambaro; M de Ladurantaye; M C J Quinn; D Provencher; A-M Mes-Masson; P N Tonin
Journal:  Oncogenesis       Date:  2012-09-10       Impact factor: 7.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.